English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background:   Bromelain enhances anticancer impacts to chemotherapeutic agents. The question as to whether bromelain does promote  in-vitro  cytotoxic and proapoptotic effects of cisplatin on human prostatic carcinoma PC3 cell line was investigated.Materials and Methods:   PC3 (human prostatic carcinoma) cells were treated either single or in combination with bromelain and/or cisplatin. MTT, clonogenic assay, flow cytometry and real-time quantitative polymerase chain reaction were used to investigate cell viability, colony formation, proapoptotic potential and  p53  gene expression, respectively.Results:   Cisplatin (IC 10 ) combined with bromelain (IC 40 ) significantly affected PC3 cell viability, inhibited colony formation, as well increased  p53  proapoptotic gene expression compared to cisplatin single treatment. Nevertheless, bromelain-cisplatin chemoherbal combination did not display any additive proapoptotic effect compared to single treatments.Conclusion:   Bromelain-cisplatin chemoherbal combination demonstrated synergistic  in-vitro  anticancer effect on human prostatic carcinoma cell line, PC3, that drastically reduced required cisplatin dose.

Does Bromelain-Cisplatin Combination Afford In-Vitro Synergistic Anticancer Effects on Human Prostatic Carcinoma Cell Line, PC3?